tiprankstipranks
Trending News
More News >

Biogen price target lowered to $255 from $300 at Baird

Baird analyst Brian Skorney lowered the firm’s price target on Biogen (BIIB) to $255 from $300 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where they beat on both top and bottom line which were mitigated by questions on Leqembi growth.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue